Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000186947 | SCV000240518 | uncertain significance | not specified | 2016-05-11 | criteria provided, single submitter | clinical testing | The R483Q variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. It was not observed with any significant frequency in approximately 6,400 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. The R483Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved in mammals. However, in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Additionally, this amino acid substitution is not predicted to occur within the transmembrane region of the protein, where the vast majority of pathogenic missense variants have been identified in association with epilepsy (Steinlein et al., 2010). Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Center for Precision Medicine, |
RCV000760164 | SCV000889981 | uncertain significance | Autosomal dominant nocturnal frontal lobe epilepsy 1 | 2018-03-16 | criteria provided, single submitter | research | |
Labcorp Genetics |
RCV001231085 | SCV001403590 | benign | Autosomal dominant nocturnal frontal lobe epilepsy | 2023-10-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485264 | SCV002785737 | uncertain significance | Autosomal dominant nocturnal frontal lobe epilepsy 1; Tobacco addiction, susceptibility to | 2021-12-20 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003430734 | SCV004150890 | uncertain significance | not provided | 2022-03-01 | criteria provided, single submitter | clinical testing |